The safety and efficacy of amrubicin in the treatment of previously untreated extensive-disease small-cell ung cancer: a meta-ana ysis

Background: Extensive-disease small-cell lung cancer (ED-SCLC) has been known to be rapid progression and relapse, despite highly sensitive to chemotherapy. Amrubicin (AMR), a third-generation synthetic anthracycline, was accepted as a feasible alternative compared with the standard first-line chemo...

Full description

Saved in:
Bibliographic Details
Published inOncoTargets and therapy p. 5135
Main Authors Wu, Ji-Feng, Zhou, Jian-Jun, Li, Xin-Ai, Hu, Li-Hui, Wen, Meng-Li
Format Journal Article
LanguageEnglish
Published Dove Medical Press Limited 01.07.2019
Subjects
Anemia
Anthracyclines
Cancer
Cancer treatment
Carboplatin
Care and treatment
Chemotherapy
Comparative analysis
Diarrhea
Lung cancer
Nausea
Neutropenia
Toxicity
Vincristine
China
Online AccessGet full text

Cover

More Information
Summary:Background: Extensive-disease small-cell lung cancer (ED-SCLC) has been known to be rapid progression and relapse, despite highly sensitive to chemotherapy. Amrubicin (AMR), a third-generation synthetic anthracycline, was accepted as a feasible alternative compared with the standard first-line chemotherapy for previously untreated ED-SCLC. While, the efficacies of these amrubicin-based regimens are unsatisfactory. Aim: Our meta-analysis was performed to assess the efficacy and toxicity of first-line therapy comparing AMR and chemotherapy in patients with ED-SCLC. Methods: Electronic databases were searched for eligible trials updated on November 2018. Randomized-controlled trials assessing the efficacy and safety of AMR in ED-SCLC were included, of which the interested results were objective response rate (ORR), progressionfree survival (PFS), overall survival (OS), and adverse events (AEs). Results: A total of 6 randomized controlled trials were included in this analysis. There are no significant differences in OS (OR=1.03, 95% CI=0.66-1.60, P=0.91), PFS (OR=1.2, 95% CI=10.77-1.88, P=0.41) or ORR (OR=1.31, 95% CI=0.90-1.92, P=0.16) with AMR (OR=0.90, 95% CI=0.76-1.05, P=0.17). The most common treatment-related AEs in the AMR group are leukopenia (OR=3.13, 95% CI=1.22-7.99, P=0.02) and neutropenia (OR=3.25, 95% CI=1.38-7.65, P=0.007). Fatigue, anemia, nausea, vomiting, diarrhea the difference between the two groups had no statistical significance. Conclusion: The results of our analysis indicated that AMR therapy demonstrated non-inferiority to the standard first-line chemotherapy for previously untreated ED-SCLC. Whether it can be accepted as an alternative regimen to the standard first-line chemotherapy is still warranted. Keywords: small-cell lung cancer, extensive-disease, amrubicin, meta-analysis
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S200601